[go: up one dir, main page]

WO2001005392A3 - Method for treating chronic pain using mek inhibitors - Google Patents

Method for treating chronic pain using mek inhibitors Download PDF

Info

Publication number
WO2001005392A3
WO2001005392A3 PCT/US2000/018347 US0018347W WO0105392A3 WO 2001005392 A3 WO2001005392 A3 WO 2001005392A3 US 0018347 W US0018347 W US 0018347W WO 0105392 A3 WO0105392 A3 WO 0105392A3
Authority
WO
WIPO (PCT)
Prior art keywords
chronic pain
treating chronic
mek inhibitors
mek
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/018347
Other languages
French (fr)
Other versions
WO2001005392A2 (en
Inventor
Alistair Dixon
Kevin Lee
Robert Denham Pinnock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to PL00352684A priority Critical patent/PL352684A1/en
Priority to AU57860/00A priority patent/AU5786000A/en
Priority to EP00943383A priority patent/EP1202726A2/en
Priority to KR1020027000609A priority patent/KR20020012315A/en
Priority to NZ515567A priority patent/NZ515567A/en
Priority to JP2001510449A priority patent/JP2003504400A/en
Priority to IL14761900A priority patent/IL147619A0/en
Priority to CA002374052A priority patent/CA2374052A1/en
Publication of WO2001005392A2 publication Critical patent/WO2001005392A2/en
Publication of WO2001005392A3 publication Critical patent/WO2001005392A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)

Abstract

The invention features a method for treating chronic pain using a compound of formula (I) and 1 (A) which are shown in claim 1 and 26 of the application.
PCT/US2000/018347 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors Ceased WO2001005392A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL00352684A PL352684A1 (en) 1999-07-16 2000-07-05 Method of treating chronic pain with MEK inhibitors
AU57860/00A AU5786000A (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors
EP00943383A EP1202726A2 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors
KR1020027000609A KR20020012315A (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors
NZ515567A NZ515567A (en) 1999-07-16 2000-07-05 Method for treating chronic pain using MEK inhibitors
JP2001510449A JP2003504400A (en) 1999-07-16 2000-07-05 Method for treating chronic pain using MEK inhibitor
IL14761900A IL147619A0 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors
CA002374052A CA2374052A1 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14429299P 1999-07-16 1999-07-16
US60/144,292 1999-07-16

Publications (2)

Publication Number Publication Date
WO2001005392A2 WO2001005392A2 (en) 2001-01-25
WO2001005392A3 true WO2001005392A3 (en) 2001-07-19

Family

ID=22507940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018347 Ceased WO2001005392A2 (en) 1999-07-16 2000-07-05 Method for treating chronic pain using mek inhibitors

Country Status (16)

Country Link
EP (1) EP1202726A2 (en)
JP (1) JP2003504400A (en)
KR (1) KR20020012315A (en)
CN (1) CN1373660A (en)
AR (1) AR024732A1 (en)
AU (1) AU5786000A (en)
CA (1) CA2374052A1 (en)
CO (1) CO5300398A1 (en)
HU (1) HUP0202623A3 (en)
IL (1) IL147619A0 (en)
NZ (1) NZ515567A (en)
PE (1) PE20010545A1 (en)
PL (1) PL352684A1 (en)
TR (1) TR200200082T2 (en)
WO (1) WO2001005392A2 (en)
ZA (1) ZA200109907B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219753C (en) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 Oxygenated esters of 4-iodoanilinophenylhydroxamic acid
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JPWO2005035493A1 (en) * 2003-10-08 2006-12-21 帝人ファーマ株式会社 Process for producing aminopyrrolidine derivative and intermediate compound
RU2352558C2 (en) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Polymorphic form of n-[(r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
WO2005051300A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1967516B1 (en) 2005-05-18 2009-11-04 Array Biopharma, Inc. 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
CA2622755C (en) 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
DK2054418T3 (en) 2006-07-06 2012-02-27 Array Biopharma Inc Dihydrothienopyrimidines as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
SI2049500T1 (en) 2006-07-06 2012-01-31 Array Biopharma Inc CYCLOPENTA ?áD?å PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
EP2101759B1 (en) 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
MX2009014013A (en) 2007-07-05 2010-01-28 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors.
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN101868443A (en) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-phenyl anthranilic acid derivatives and uses thereof
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
ES2422733T3 (en) 2008-01-09 2013-09-13 Array Biopharma Inc Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
PL2531502T3 (en) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
WO2012135779A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
GEP201706690B (en) 2012-10-12 2017-06-26 Exelixis Inc Novel process for making compounds for use in treatment of cancer
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP7080812B2 (en) 2015-10-27 2022-06-06 アセチロン ファーマシューティカルズ インコーポレイテッド HDAC inhibitors for the treatment of diabetic peripheral neuropathy
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2020306249B2 (en) * 2019-06-28 2025-06-26 University Of Copenhagen Treatment of CNS disorders with sleep disturbances

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1999001421A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
WO2000035436A2 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1999001421A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
WO2000035436A2 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A N GAIDUKEVICH ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF N-PHENYLANTHRANILIC ACID", STN CHEMICAL ABSTRACTS,XX,XX, vol. 11, no. 103, 16 September 1985 (1985-09-16), XP002063638 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRYGLEWSKI, R. J.: "Structure-activity relations of some prostaglandin synthetase inhibitors", XP002157064, retrieved from STN Database accession no. 83:126083 *
DUESBERY N S ET AL: "MEK WARS, A NEW FRONT IN THE BATTLE AGAINST CANCER", NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 5, no. 7, 1999, pages 736 - 737, XP000907246, ISSN: 1078-8956 *
DUNCIA J V ET AL: "MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 8, no. 20, 20 October 1998 (1998-10-20), pages 2839 - 2844, XP004139571, ISSN: 0960-894X *
JI RU-RONG ET AL: "Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity.", NATURE NEUROSCIENCE, vol. 2, no. 12, December 1999 (1999-12-01), pages 1114 - 1119, XP000978586, ISSN: 1097-6256 *
KHALIFA M.: "Synthesis and biological activity of certain Derivatives of 2,4- dioxo- 1,2,3,4 tetrahydroquinazoline", PHARMAZIE, vol. 37, no. 2, 1982, pages 115 - 117, XP002157063 *
KHALIFA, M. ET AL: "Synthesis and biological activity of certain derivatives of 2,4-dioxo-1,2,3,4-tetrahydroquinazoline. Part 2", EGYPT. J. CHEM. (1983), VOLUME DATE 1982, 25(3), 285-91, XP000978530 *
MOKHORT N A: "DEPENDENCE BETWEEN STRUCTURE, ANTIINFLAMMATORY, ANALGESIC, AND ANTIPYR", CHEMABS, AN = 1972:121461, 1972, XP002142610 *
PROSTAGLANDIN SYNTH. INHIBITORS - THEIR EFF. PHYSIOL. FUNCT. PATHOL. STATES, [INT. SYMP.] (1974), MEETING DATE 1973, 33-52. EDITOR(S): ROBINSON, HARRY J.;VANE, JOHN R. PUBLISHER: RAVEN, NEW YORK, N. Y. *
T I SHUL'GA ET AL: "SYNTHESIS AND PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES OF DIPHENYLAMINE-2-CARBOXYLIC ACID DERIVATIVES", STN CHEMICAL ABSTRACTS,XX,XX, vol. 17, no. 109, 24 October 1988 (1988-10-24), XP002063639 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors

Also Published As

Publication number Publication date
HUP0202623A3 (en) 2003-03-28
HUP0202623A2 (en) 2002-11-28
AU5786000A (en) 2001-02-05
WO2001005392A2 (en) 2001-01-25
PL352684A1 (en) 2003-09-08
ZA200109907B (en) 2003-02-28
IL147619A0 (en) 2002-08-14
KR20020012315A (en) 2002-02-15
EP1202726A2 (en) 2002-05-08
CN1373660A (en) 2002-10-09
NZ515567A (en) 2004-03-26
TR200200082T2 (en) 2002-04-22
PE20010545A1 (en) 2001-06-04
CA2374052A1 (en) 2001-01-25
CO5300398A1 (en) 2003-07-31
AR024732A1 (en) 2002-10-23
JP2003504400A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
WO2001005390A3 (en) Method for treating chronic pain using mek inhibitors
WO2001005391A3 (en) Method for treating chronic pain using mek inhibitors
WO2001005393A3 (en) Method for treating chronic pain using mek inhibitors
WO1999005096A3 (en) Urokinase inhibitors
AU2001249881A1 (en) Method of treating the heart
HK1049656A1 (en) Fab i inhibitors
PL330782A1 (en) Method of treating carcinoma using the inhibitors of naaladase
PL353785A1 (en) Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
AU7331300A (en) Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU5838700A (en) Method for treating and preventing finger disorders
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU6260999A (en) Methods of treating chronic pain
AU5038299A (en) Process for the biocidal treatment of surfaces
AU6771798A (en) Method for treatment of chronic bronchitis
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU6047099A (en) Compositions and methods for the treatment of chronic lymphocytic leukemia
AU6187898A (en) Method for preventing or treating low renin hypertension by administering an endothelin antagonist
WO2002083151A3 (en) Compositions and methods for treating an arthritic condition
ZA200107523B (en) Method for improving the stability of stored and/or light-sensitive therapeutic systems or component thereof.
AU2001243297A1 (en) Method for treating or preventing depression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809801.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2374052

Country of ref document: CA

Ref document number: 2374052

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 515567

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 57860/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001/09907

Country of ref document: ZA

Ref document number: 200109907

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000943383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 147619

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020027000609

Country of ref document: KR

Ref document number: 2002/00082

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020027000609

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000943383

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000943383

Country of ref document: EP